Two randomised clinical trials provided direct evidence to support administration of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) for blood pressure control among PAD patients (Sleight, 2000; Yusuf et al., 2008). Here, ACE is linked to peripheral arterial disease.